Skip to content
Screener

Rigel Pharmaceuticals RIGL Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$19.23M+9.3%
Nuvation Bio logo
Nuvation BioNUVB
$1.72M-5.1%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$626K+19.2%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$1.39M+123%
Opko Health logo
Opko HealthOPK
$11.01M+11.0%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$75K-2.6%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K—
Free cash flow-$22.0M—

Valuation

See full
Market cap$750.37M+25.0%
Enterprise value$794.27M+44.9%
P/E2.1×-4.1×
P/S2.5×+0.3×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%—

Returns & leverage

See full
Return on equity174.1%—
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032
Line itemAs of / March 31, 2026As of / December 31, 2025 ⁽¹⁾
Revenue reserves and refund liability28,08027,716
Loans payable, net, current portion29,86529,812
Other accrued liabilities9,67411,466
Lease liabilities, current portion636614
Total current liabilities89,49299,237
Long-term portion of lease liabilities228395
Long-term portion of loans payable, net14,99122,482
Total liabilities104,711122,114

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's operating lease liabilities (current)?
Rigel Pharmaceuticals (RIGL) reported operating lease liabilities (current) of $636K in Q1 2026.
How has Rigel Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
Rigel Pharmaceuticals's operating lease liabilities (current) increased by 39.5% year-over-year, from $456K to $636K.
What is the long-term trend for Rigel Pharmaceuticals's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Rigel Pharmaceuticals's operating lease liabilities (current) has grown at a -41.0% compound annual growth rate (CAGR), from $8.62M to $614K.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Rigel Pharmaceuticals's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude